Last quarter Celgene (NASDAQ:CELG) fell short of Wall Street estimates, and it is scheduled to report again on Thursday.
Continue Reading Below
Analysts currently expect Celgene to come in with earnings of $1.06 per share on revenues of $1.35 billion. Analysts gave estimates ranging from earnings per share to earnings per share.
The stock fell $7.71 per share between June 20, 2012 and June 21, 2012. Looking at change over the last three months, April 25, 2012 and July 20, 2012, the stock price fell $11.49 (-14.7%), from $77.91 to $66.42.
Company Fundamental Trends
Analysts are bullish on the stock as 22 analysts rate it as a buy and there are no sell ratings. Analyst sentiment has been waning recently, as the average rating has dropped slightly over the past three months.
Last Quarter's Results
In the first quarter, profit rose 57.1% to $401.5 million (90 cents a share) from $255.6 million (54 cents a share) the year earlier, but fell short analyst expectations. Revenue rose 13.2% to $1.27 billion from $1.13 billion.
Reporting Period: 2Q
Date of Release: Thursday, July 26, 2012 before market open
Revenue Estimate: $1.35 billion
(Company fundamentals by Xignite Financials. Earnings estimates provided by Zacks)